Drugs / Measles-Rubella vaccine
Measles-Rubella vaccine
also known as
Measles-Rubella Virus Vaccine Live US Pharmacopeia (USP) · MR vaccine · MRV-MNP · MRV-SC
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06815835 | Apr 2025 → Mar 2026 overdue | measles, rubella, yellow fever | International Centre for Diarrhoeal Disease Research, Bangladesh | Not yet recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02153866 | Dec 2013 → May 2014 | Rotavirus infection | Sichuan Center for Disease Control and Prevention | Unknown | No outcome recorded |
| Phase 4 | NCT01700621 | Jan → Sep 2013 | Rotavirus infection | PATH | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06816524 | Jan 2026 → Dec 2027 expected | disorder of iron metabolism and transport | Nicole Stoffel | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT04394689 Comparator | May 2021 → Nov 2022 | measles, rubella | Micron Biomedical, Inc | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-05-01 | Micron Biomedical, Inc | Results Micron Biomedical Announces The Lancet Publication of Positive Phase 1/2 Data From First Clinical Trial of Needle-Free Vaccines in Children micronbiomedical.com ↗
The landmark study demonstrated positive safety and immunogenicity of Micron’s MR vaccine microarray technology in the first study of its kind in adults and children as young as nine months. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-05-01 | Micron Biomedical, Inc | Micron Biomedical Announces The Lancet Publication of Positive Phase 1/2 Data From First Clinical Trial of Needle-Free Vaccines in Children micronbiomedical.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Measles-Rubella vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06815835 ↗ |
| Known as | Measles-Rubella Virus Vaccine Live US Pharmacopeia (USP) | “Measles-Rubella Virus Vaccine Live US Pharmacopeia (USP)” NCT01700621 ↗ |
| Known as | MR vaccine | “To evaluate the immunological non-interference of co-administration of Measles and Rubella vaccine (Live) I.P. (Freeze Dried) \[MR vaccine\] of M/s. Zydus Lifesciences Ltd....” NCT06815835 ↗ |
| Known as | MRV-MNP | “measles and rubella vaccine microneedle patches (MRV-MNP), in which the vaccine is embedded in dissolving microneedles” PMID 36104719 ↗ Sep 2022 |
| Known as | MRV-SC | “Measles Rubella Vaccine (MRV-SC)” NCT04394689 ↗ |
| Modality | Vaccine | “live attenuated measles-rubella vaccine” NCT01700621 ↗ |
| Route | Subcutaneous | “one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine” NCT01700621 ↗ |